Cigna Group（CI）資訊與事件

$278.880

+1.227 (+0.44%)收盤時

CI 資訊

8.508-27CNBC

Talarico Unveils Healthcare Reform Plan to Combat Monopolies

8.508-26PRnewswire

Cigna Launches Industry-First Connected Benefits Experience

8.508-26Newsfilter

Cigna Launches Industry-First Smart Coverage Plan

7.508-18CNBC

Costco Partners with SCAN Group to Launch Medicare Advantage Plan

6.508-09Yahoo Finance

Analysis of Promising and Underperforming S&P 500 Stocks

6.508-09Yahoo Finance

Cigna Group Stock Valuation Analysis

9.508-09Yahoo Finance

Cigna Group Reports Q2 Earnings and Buyback Update

6.008-04CNBC

Major Rating Changes on Wall Street

7.508-01CNBC

Retail Pharmacies Compete for GLP-1 Market Share in the U.S.

9.507-31CNBC

Microsoft's Market Cap Soars by $450 Billion After 15% Surge

查看更多資訊

CI 事件

7/30 06:30

Cigna Group Expects 2026 Adjusted EPS of At Least $30.45

Consensus $30.41. The company said, "The Cigna Group's outlook for full year 2026 consolidated adjusted income from operations is at least $30.45 per share. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026 dividends."

7/30 06:30

Cigna Reports Q2 Revenue of $71.67B

Reports Q2 revenue $71.67B, consensus $70.18B. "Our purpose is to improve the lives of each and every customer and patient we serve," said Brian C. Evanko, President and Chief Executive Officer of The Cigna Group. "By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution."

7/14 15:00

FTC Reaches $8.5 Billion Settlement with Caremark

The Federal Trade Commission secured a settlement agreement with one of the nation's largest pharmacy benefit managers and its affiliated entities, marking yet another important victory in the Commission's fight to lower healthcare costs for Americans. Caremark Rx LLC and Zinc Health Services LLC have agreed to a settlement agreement that requires the PBM to adopt changes to its business practices to drive down patients' out-of-pocket costs, increase transparency and ensure community pharmacies are treated fairly. "The FTC under President Trump won't stand for anticompetitive behavior that drives up prices for American consumers," said Chairman Andrew N. Ferguson. "The settlement with Caremark brings billions in real savings to consumers feeling the pinch from excessive prescription drug prices. And the settlement bars Caremark from interfering with hub pharmacies, which can help identify the lowest out-of-pocket option for patients and improve patient access to prescriptions. Today's action builds on previous wins for President Trump's healthcare agenda, including innovations like TrumpRx to make prescription drug prices more transparent and affordable for everyone."The FTC's settlement with Caremark locks in place up to $8.5B in consumer savings over the next 10 years and unlocks up to $4.5B in additional savings for patients over the same 10-year period from point-of-sale rebates. Like the Commission's settlement with Express Scripts Inc. (CI), the Caremark settlement similarly delinks PBM fees from drug list prices, enhances transparency and provides retail community pharmacies with the opportunity to shift to a cost-plus reimbursement model. Additionally, the settlement addresses concerns that Caremark, a subsidiary of CVS Health Corporation (CVS), interfered with patient and pharmacy access to hub pharmacy services, which can help patients achieve more convenient, transparent and affordable access to prescription drugs.

7/14 13:30

Justice Department Expands Antitrust Investigation into Claritev

The Justice Department is expanding an antitrust investigation into Claritev over allegations the company helped insurers, including UnitedHealth (UNH), CVS Health's (CVS) Aetna and Cigna (CI), illegally coordinate to reduce out-of-network reimbursement rates, Josh Sisco, Leah Nylen and Ike Swetlitz of Bloomberg report, citing people with knowledge of the matter. The Justice Department recently sent civil investigative demands to lawyers for a group of hospitals and doctor groups suing Claritev for alleged antitrust violations, sources told Bloomberg. The antitrust division is seeking information the providers are collecting during the litigation, people told the news agency. The Justice Department's inquiry involves similar allegations as the private litigation, the sources added. Shares of Claritev are down 10% to $26.92 following the report.

6/23 11:00

Justice Department to Charge 450 Defendants in $6.5B Healthcare Fraud

The Justice Department is expected to charge around 450 defendants for alleged healthcare fraud totaling over $6.5B, The Wall Street Journal's Sabrina Siddiqui and Christopher Weaver reports. The operation spans 57 federal-court districts and 41 states, including 90 medical professionals and over 100 Medicaid fraud defendants, according to the report, which adds that the Justice Department will unveil new data-sharing agreements with the FTC, Homeland Security, and CMS to expand fraud detection. Publicly traded companies in the space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH).

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。